Moderna

Overview

Biotechnology company whose mRNA personalized cancer vaccine (PCV) sequences each patient's tumor to identify up to 34 unique neoantigens and manufactures a custom construct in six weeks, with ASCO 2026 data showing 49% reduction in recurrence/death with pembrolizumab. Moderna's personalized cancer vaccine (PCV) sequences each patient's tumor to identify up to 34 unique neoantigens and builds a custom mRNA construct within six weeks, with every dose manufactured for a single patient — representing a 'bench to one' production model that redefines the manufacturing challenge for the bioprocessing industry. Data presented at ASCO in June 2026 showed that Moderna's personalized cancer vaccine combined with pembrolizumab reduced the risk of cancer recurrence or death by approximately 49% in the reported patient population. (Segment 1 (00:00-05:00))